UK Moratorium on Use of Genetic Tests by Insurers Extended
By Philippa Brice,
PHG Foundation
| 01. 21. 2015
Untitled Document
The UK Government and Association of British Insurers (ABI) have agreed to extend their voluntary moratorium on the use of predictive genetic test results by insurers by another two years, to 2019.
Originally established in 2001 and periodically reviewed and renewed ever since, the Concordat and Moratorium on Genetics and Insurance is a voluntary agreement intended to protect the interests of both individuals (by ensuring appropriate access to insurance) and of insurers (by ensuring access to information about risks).
Once again, there has been no significant change to the substance of the agreement; individuals must only disclose genetic test results to insurers in the case of Huntington’s disease tests and for life insurance policies worth in excess of £500,000. It is worth noting that anyone undertaking a genetic test for Huntington’s disease almost certainly does so in the face of a family history of the condition, which must be disclosed to insurers anyway.
However, the concordat contains two new elements. An additional Annex 2 explains the important distinction between predictive and diagnostic genetic tests. Predictive or presymptomatic...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...